secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001683168-24-007929
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Q3 net loss $0.4M, R&D down 64% to $0.4M, cash $6.8M; advancing DNase platform toward Phase 1
--------------------------------------------------------------------------------

- Net loss of $0.4M for Q3 2024; no material revenue reported.
- R&D expenses fell 63.9% YoY to $0.4M from $1.0M due to lower process development spending.
- Cash and equivalents were $6.8M at September 30, 2024.
- Preclinical data for DNase I combination therapies in colorectal cancer models completed; presented at SITC 2024.
- Strategic focus on institutional partnerships with Tokyo Medical University and Scripps Research Institute.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824007929/0001683168-24-007929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824007929/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-007929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer